Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2016-10-05 Earnings Release
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Bone Therapeutics annonce des données d’efficacité positives pour l’étude de Phase IIA dans la fusion vertébrale
Earnings Release Classification · 92% confidence The document is a press release dated October 5, 2016, announcing positive efficacy data from a Phase IIA study for the ALLOB® product in spinal fusion. It details clinical trial results (primary and secondary endpoints met), provides commentary from the CEO, and includes background information on the procedure and the company. This format—a formal announcement of key periodic results (clinical trial data) intended for immediate public disclosure—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a specific announcement of clinical trial results rather than a full quarterly/interim financial report (IR) or a transcript (CT), and it is not a proxy statement (DEF 14A) or a formal 10-K, the most fitting category for a press release detailing key performance/study outcomes is 'Earnings Release' (ER), as it serves the function of releasing period-specific performance highlights to the market. Given the context of clinical trial data release, it functions similarly to an earnings release announcing operational/study milestones. If a more specific 'Clinical Trial Result Announcement' existed, it would be preferred, but among the given options, ER is the closest fit for a major, time-sensitive operational update. Q4 2016
2016-10-05 French
Bone Therapeutics kondigt positieve doeltreffendheidsresultaten aan voor de Fase IIA studie in vertebrale fusie
Earnings Release Classification · 95% confidence The document is a press release dated October 5, 2016, announcing positive efficacy results from a Phase IIA clinical study for a product called ALLOB® in vertebral fusion. It details study outcomes (primary and secondary endpoints met), quotes the CEO, provides background on the condition and the treatment, and includes standard boilerplate information about the company and contact details. This format—a formal announcement of key operational/clinical results outside of a mandated periodic financial filing (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses specifically on clinical trial results and business progress rather than just financial figures, and it is a formal announcement, it fits best under the 'Earnings Release' category, which often encompasses major operational updates, or potentially 'Regulatory Filings' (RNS) if it were a mandatory filing. Given the structure and content (announcing results and outlook), ER is the most appropriate fit among the specific options, as it serves as the primary communication of recent performance/progress to the market. It is not a full financial report (10-K or IR), a transcript (CT), or a presentation (IP). Q4 2016
2016-10-05 Dutch
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is titled as an announcement regarding a 'positive ruling on Belgian Patent Income Deduction' and is dated September 15, 2016. It details a specific tax benefit (PID) related to patent revenues for products like PREOB® and ALLOB®. The structure, content (announcement of a specific corporate/regulatory event, quotes from management, boilerplate 'About Us' section, and contact details), and the explicit label 'Press release' at the end strongly indicate this is a general corporate announcement intended for immediate public disclosure, rather than a comprehensive statutory report like a 10-K or IR. Since it is a specific, material announcement that doesn't fit the definitions for ER (Earnings Release), CAP (Financing), or DIV (Dividend), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements not covered by more specific codes.
2016-09-15 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Legal Proceedings Report Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific corporate event: Bone Therapeutics benefiting from the Belgian Patent Income Deduction (PID) tax regime. This is a specific, non-periodic announcement concerning financial/tax status, rather than a comprehensive annual report (10-K), quarterly report (IR), or standard earnings release (ER). It is not a transcript (CT), director dealing (DIRS), or dividend notice (DIV). Since it is a specific, material announcement that doesn't fit the primary financial report categories, it is best classified as a general Regulatory Filing (RNS), as it is a formal communication to the market about a material development, often released via regulatory channels when a more specific code isn't applicable. It is too detailed to be a simple Report Publication Announcement (RPA) which usually just announces the release of another document.
2016-09-15 French
Document availability communications / Half yearly financial report
Earnings Release Classification · 95% confidence The document is an announcement of H1 2016 financial results for Bone Therapeutics. It contains key financial highlights, operational updates, and a consolidated statement of comprehensive income. While it references a full interim report available on their website, the document itself provides the core financial data and business highlights typical of an earnings release. It is not a full interim report (which would be much longer and include full notes to the financial statements), but rather the initial announcement of those results. H1 2016
2016-08-30 English
Communiqués de mise à disposition de documents / Modalités de mise à disposition du rapport financier semestriel
Earnings Release Classification · 99% confidence The document explicitly states: 'Bone Therapeutics publie ses résultats du premier semestre 2016' (Bone Therapeutics publishes its results for the first half of 2016) and 'annonce aujourd'hui la publication de ses résultats opérationnels et financiers pour le semestre clos le 30 juin 2016' (announces today the publication of its operational and financial results for the semester ended June 30, 2016). This content is a comprehensive financial report covering a period shorter than a year (six months), which aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it mentions a conference call (CT) and provides key figures, the core document is the detailed semi-annual financial report itself, not just the announcement of its release (RPA) or a transcript (CT). H1 2016
2016-08-30 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.